Inflammation is a complex process involving many aspects of biology.
Recent advances in the field of immuno-oncology, such as CAR-T, are driving how we harness the immune system to fight disease.
The majority of our assays use primary human cells to monitor changes in proliferation and signaling pathways. B cells, T cells, Peripheral Blood Mononuclear cells (PBMCs), and dendritic cells are all available.
We’ve invested heavily in the right tools to help you get the data you need. Using the latest high resolution confocal systems we can measure cellular infiltration into solid tumors.
T-cell activation is a key component of CAR (chimeric antigen receptor). The first CAR T cells were developed at the Weizmann Institute of Science in Israel in the late 1980s by chemist and immunologist Zelig Eshhar.
Our automated imaging based assays assess T cell receptor activation (example shown above in red) by measuring the clustering of receptors on the plasma membrane. Our assays can be multiplexed with other relevant markers depending on the type of CAR-T approach used.